CMS has aggressive 2030 goals to transform how care is provided by moving patients and providers toward accountable models of ...
Devices that are approved through a process that does not require any clinical evidence for FDA authorization should not ...
The immediate aftermath of the 2024 presidential election has brought renewed attention to regulatory policy at the U.S. Food ...
Caremark, Express Scripts, and OptumRx continue to defend themselves against a Federal Trade Commission administrative ...
Medicare drug price negotiation could have significant impacts on investment in post-approval studies for cancer treatment ...
On September 26, 2024, the White House released an executive order allowing states to use Medicaid to reimburse health care ...
Health Affairs announced today that Editor-in-Chief Alan Weil will leave his role at the end of the year.
Key policies introduced over the past 45 years have brought new research organizations and investors into the pharmaceutical ...
Effective enforcement of the Hospital Price Transparency Rule can empower patients, foster competition, and help control ...
A vetoed California bill offers a case study for future legislative attempts to address private equity involvement in health ...
In this article, we describe what’s new in Medicare Advantage Organizations' (MAOs’) PY2025 nonmedical benefit offerings and ...
States can align capitation withholds with value-based payment state-directed payment arrangements to incentivize managed ...